Having deciphered you posts, I suspect the Starpharma management understand the significance of HER2-DEP as much as you do. Which makes me think that no announcements will be made regarding DEP DOC until the VivaGel ph3 results are published. Assuming the VG trials are a success, and the share price rises in line with a commercial agreement, then anyone contemplating a bid for the company would meet a lot more resistance than at present. I certainly don't want to see SPL crushed by the big boys.
DEP-Trastuzumab, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.007(7.14%) |
Mkt cap ! $43.29M | |||
| Open | High | Low | Value | Volume |
| 9.5¢ | 10.5¢ | 9.5¢ | $8.154K | 83.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5102 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 124847 | 3 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |